Abstract:
The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.
Abstract:
The present disclosure generally relates to cache memory systems and/or techniques to identify dead cache blocks in cache memory systems. Example systems may include a cache memory that is accessible by a cache client. The cache memory may include a plurality of storage locations for a first cache block, with a most recently used position location in the cache memory. A cache controller may be configured to predict whether the first cache block stored in the cache memory is identified as a dead cache block based on a cache burst of the first cache block. The cache burst may comprise a first access of the first cache block by a cache client and any subsequent contiguous accesses of the first cache block following the first access by the cache client while the first cache block is in a most recently used position of the cache set.
Abstract:
The present disclosure generally relates to systems for routing data across a multinodal network. Example systems include a multinodal array having a plurality of nodes and a plurality of physical communication channels connecting the nodes. At least one of the physical communication channels may be configured to route data from a first node to two or more other destination nodes of the plurality of nodes. The present disclosure also generally relates to methods for routing data across a multinodal network and computer accessible mediums having stored thereon computer executable instructions for performing techniques for routing data across a multinodal network.
Abstract:
Anti-nematode compounds, compositions, and methods for identifying such compound are disclosed, where the compounds have the formula I: where Q, Q', R 1 , R 2 , and n are defined herein
Abstract:
The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.
Abstract:
The present invention provides a Mycoplasma pneumoniae community acquired respiratory distress syndrome (CARDS) toxin, biologically active fragments/domains of the CARDS toxin, antibodies to the CARDS toxin and nucleic acids encoding the CARDS toxin. Also provided are methods of diagnosing, treating and/or preventing infection by Mycoplasma pneumoniae using the compositions provided herein.
Abstract:
C-Raf inhibitors, especially oxindole derivatives such as 5-lodo-3-[(3,5dibromo-4-hydroxyphenyl) methylene]-2-indolinone, are used for the prevention or inhibition of neuronal cell death in a mammal suffering from or susceptible to neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury, epilepsy-associated neuronal loss, paralysis, or spinal cord injury. C-Raf inhibitors are included in the manufacture of compositions for the treatment of neurodegenerative disease, cerebral ischaemia, traumatic neuronal injury, epilepsy-associated neuronal loss, paralysis, or spinal cord injury.
Abstract:
The present invention includes a method and composition of storing and preserving biofilms for input and output of high-density information. One form of the present invention is a fabricated biofilm storage device with a biologic material applied to a substrate to form, e.g., a dry thin film stable at room temperature for extended periods of time. Another form of the present invention is a method of fabricating a biofilm storage device in which a biologic material is applied to a substrate under conditions that promote alignment of the biologic material on the substrate. The composition, method, and kit of the present invention have universal application in biologics, magnetics, optics and microelectronics.
Abstract:
The present invention includes methods of producing magnectic na nocrystals by using a biological molecule that has been modified to possess an amino acid oligomer that is capable of specific b inding to a magnectic material.